Answer
Fluvoxamine at the tested dose of 50 mg increased roflumilast’s total PDE4 inhibitory activity by 59%; combining them may increase exposure and cause persistent intolerability, in which case roflumilast treatment should be reassessed.
Sources for this answer
- DAXAS 500 micrograms film-coated tabletsAstraZeneca UK Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 16Document updated
Sources checked